Skip to main content
Contact Us
Subscribe
E-Edition
55°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Best of 2024
Archives
2025 Calendar Photos
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Antibe Therapeutics Inc
(OP:
ATBPF
)
N/A
UNCHANGED
Last Price
Updated: 3:46 PM EDT, Apr 8, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Antibe Therapeutics Inc
< Previous
1
2
Next >
Antibe Announces Granting of Initial Order Under Companies' Creditors Arrangement Act
April 09, 2024
From
Antibe Therapeutics Inc.
Via
Business Wire
Antibe to File an Application for an Initial Order Under Companies' Creditors Arrangement Act
April 09, 2024
From
Antibe Therapeutics Inc.
Via
Business Wire
Antibe Announces FDA Clinical Hold on Otenaproxesul and Legal Action by Nuance
April 01, 2024
From
Antibe Therapeutics Inc.
Via
Business Wire
Antibe to Present Otenaproxesul PK/PD Results at the ASRA Pain Medicine Meeting
March 20, 2024
From
Antibe Therapeutics Inc.
Via
Business Wire
Antibe to Present Otenaproxesul PK/PD Results at the American Academy of Pain Medicine Meeting
March 07, 2024
From
Antibe Therapeutics Inc.
Via
Business Wire
Antibe Announces Unfavorable Decision in Arbitration With Nuance Pharma
March 04, 2024
From
Antibe Therapeutics Inc.
Via
Business Wire
Antibe Reports Q3 2024 Interim Financial and Operating Results
February 14, 2024
From
Antibe Therapeutics Inc.
Via
Business Wire
Antibe Extends Early Warrant Exercise Incentive Program
February 01, 2024
From
Antibe Therapeutics Inc.
Via
Business Wire
Antibe Announces Early Warrant Exercise Incentive Program
December 29, 2023
From
Antibe Therapeutics Inc.
Via
Business Wire
OTC Markets Group Announces the 2024 OTCQX Best 50
January 18, 2024
From
OTC Markets
Via
GlobeNewswire
Antibe Therapeutics Announces Amendment to Warrant Terms
December 12, 2023
From
Antibe Therapeutics Inc.
Via
Business Wire
Antibe Reports Q2 2024 Interim Financial and Operating Results
November 13, 2023
From
Antibe Therapeutics Inc.
Via
Business Wire
Antibe Reports PK Results of First Clinical Study of Otenaproxesul’s New Formulation
November 09, 2023
From
Antibe Therapeutics Inc.
Via
Business Wire
Antibe Completes First Clinical Study of Otenaproxesul’s New Formulation
November 01, 2023
From
Antibe Therapeutics Inc.
Via
Business Wire
Antibe Initiates First Clinical Study of Otenaproxesul’s New Formulation
October 18, 2023
From
Antibe Therapeutics Inc.
Via
Business Wire
Antibe Receives Approval to Initiate PK/PD Study of Otenaproxesul
September 28, 2023
From
Antibe Therapeutics Inc.
Via
Business Wire
Antibe Announces Results of 2023 Annual Meeting
September 08, 2023
From
Antibe Therapeutics Inc.
Via
Business Wire
Antibe Reports Q1 2024 Interim Financial and Operating Results
August 14, 2023
From
Antibe Therapeutics Inc.
Via
Business Wire
Antibe Reports 2023 Year-End Results and Business Highlights
June 29, 2023
From
Antibe Therapeutics Inc.
Via
Business Wire
Antibe’s Chief Medical Officer to Present at the 2023 Precision in Clinical Trials Summit
April 25, 2023
From
Antibe Therapeutics Inc.
Via
Business Wire
Antibe to Present at the 2023 Bloom Burton & Co. Healthcare Investor Conference
April 18, 2023
From
Antibe Therapeutics Inc.
Via
Business Wire
Antibe Provides April 2023 Corporate Update
April 11, 2023
From
Antibe Therapeutics Inc.
Via
Business Wire
Antibe Reports Q3 2023 Interim Financial and Operating Results
February 15, 2023
From
Antibe Therapeutics Inc.
Via
Business Wire
Antibe Reports Q2 2023 Interim Financial and Operating Results
November 15, 2022
From
Antibe Therapeutics Inc.
Via
Business Wire
Antibe Closes Previously Announced Strategic Sale of Citagenix Subsidiary
November 02, 2022
From
Antibe Therapeutics Inc.
Via
Business Wire
Antibe Provides Development Update for Otenaproxesul
October 12, 2022
From
Antibe Therapeutics Inc.
Via
Business Wire
Antibe Announces Results of 2022 Annual Meeting
September 09, 2022
From
Antibe Therapeutics Inc.
Via
Business Wire
Antibe Academic Collaborator to Present Clinical Data at PAINWeek 2022
September 06, 2022
From
Antibe Therapeutics Inc.
Via
Business Wire
Antibe Therapeutics Reports Q1 2023 Interim Financial and Operating Results
August 15, 2022
From
Antibe Therapeutics Inc.
Via
Business Wire
Antibe Therapeutics Reports 2022 Year-End Results and Business Highlights
June 30, 2022
From
Antibe Therapeutics Inc.
Via
Business Wire
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
